VP16-213 (Etoposide)

Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs

1978 • 982 citations

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

1978 • 166 citations

Etoposide (VP-16-213)

1979 • 151 citations

SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIA

1973 • 148 citations

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

1979 • 142 citations

VM 26 and VP 16–213: A comparative analysis

1977 • 122 citations

Pharmacokinetics of VP16-213 given by different administration methods

1982 • 121 citations

VP16-213 as a single agent in advanced testicular tumors

1980 • 112 citations

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1975 • 97 citations

Podophyllotoxin derivative VP 16-213

1979 • 86 citations

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

1980 • 69 citations

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1977 • 58 citations

VP 16-213 in acute myelogenous leukaemia

1976 • 55 citations

Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

1982 • 50 citations

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

1978 • 47 citations

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

1976 • 45 citations

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

1981 • 44 citations

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

1972 • 42 citations

The delta and epsilon errors in the assessment of cancer clinical trials.

1979 • 34 citations

Phase II study of oral VP-16-213 in hepatocellular carcinoma

1981 • 34 citations

Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy

1982 • 29 citations

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.

1976 • 26 citations

PHASE I clinical trial of an oral solution of VP-16-213.

1976 • 25 citations

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

1974 • 23 citations

Analysis and interpretation of response rates for anticancer drugs.

1979 • 21 citations

Phase I trial of a new form of an oral administration of VP-16-213.

1979 • 21 citations

Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076).

1966 • 18 citations

Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.

1975 • 17 citations

Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.

1973 • 16 citations

[Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].

1975 • 13 citations

Randomisierte Phase-II-Studie mit VP-16–213 (Etoposide®) in der Behandlung vom fortgeschrittenen Mammakarzinom

1981 • 12 citations

[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].

1977 • 12 citations

Die Entwicklung neuer Substanzen in der Onkologie: Viele Probleme und einige Lösungen

2008 • 1 citations

Deleted Work

1955 • 0 citations